TScan Therapeutics, Inc. (TCRX)
Largest Insider Buys in Sector
TCRX Stock Price History Chart
TCRX Stock Performance
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a …
Insider Activity of TScan Therapeutics, Inc.
Over the last 12 months, insiders at TScan Therapeutics, Inc. have bought $472,433 and sold $952,116 worth of TScan Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at TScan Therapeutics, Inc. have bought $6.79M and sold $508,034 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lynx1 Capital Management LP (10 percent owner) — $779,766. Klencke Barbara (director) — $82,550.
The last purchase of 100,000 shares for transaction amount of $290,140 was made by Lynx1 Capital Management LP (10 percent owner) on 2024‑12‑13.
List of Insider Buy and Sell Transactions, TScan Therapeutics, Inc.
| 2024-12-13 | 10 percent owner | 100,000 0.1862% | $2.90 | $290,140 | +4.21% | |||
| 2024-12-12 | 10 percent owner | 31,800 0.0595% | $3.01 | $95,629 | -1.66% | |||
| 2024-11-15 | 10 percent owner | 947 0.0016% | $4.34 | $4,114 | -4.54% | |||
| 2024-09-23 | director | 5,000 0.0104% | $5.29 | $26,450 | -4.42% | |||
| 2024-08-26 | director | 5,000 0.0109% | $5.53 | $27,650 | -7.94% | |||
| 2024-08-23 | Sale | See Remarks | 164,686 0.374% | $5.78 | $952,116 | -7.58% | ||
| 2024-08-23 | director | 5,000 0.0112% | $5.69 | $28,450 | -7.58% | |||
| 2023-12-19 | director | 317 0.0006% | $4.97 | $1,575 | +20.92% | |||
| 2023-12-18 | director | 28,830 0.0553% | $4.89 | $140,881 | +28.42% | |||
| 2023-12-14 | director | 5,000 0.01% | $5.08 | $25,400 | +18.40% | |||
| 2023-06-02 | director | 37,880 0.0391% | $2.63 | $99,564 | +77.58% | |||
| 2023-05-31 | Sale | 10 percent owner | 25,400 0.0251% | $2.52 | $63,953 | +116.52% | ||
| 2022-12-28 | Chief Financial Officer | 3,158 0.0019% | $1.56 | $4,941 | +66.11% | |||
| 2022-12-27 | Chief Financial Officer | 2,842 0.0017% | $1.50 | $4,276 | +74.70% | |||
| 2022-05-18 | Chief Executive Officer | 25,000 0.0353% | $3.59 | $89,821 | -21.23% | |||
| 2022-05-11 | 25,865 0.0202% | $1.99 | $51,350 | +36.41% | ||||
| 2022-05-10 | 22,983 0.0179% | $1.99 | $45,628 | +40.95% | ||||
| 2022-05-10 | 1.33M 0.9851% | $1.88 | $2.51M | +40.95% | ||||
| 2022-03-24 | Chief Financial Officer | 15,000 0.02% | $3.40 | $50,982 | -11.88% | |||
| 2021-09-23 | Chief Legal Officer | 4,716 0.0138% | $7.48 | $35,255 | -51.76% |
Insider Historical Profitability
| Lynx1 Capital Management LP | 10 percent owner | 5357347 10.038% | $3.04 | 3 | 1 | |
| Klencke Barbara | director | 45000 0.0843% | $3.04 | 4 | 0 | +18.4% |
| ZDRAVESKI ZORAN | See Remarks | 4716 0.0088% | $3.04 | 1 | 1 | <0.0001% |
| BAKER BROS. ADVISORS LP | 2528583 4.7378% | $3.04 | 3 | 0 | +7.69% | |
| Baker Brothers Life Sciences LP | 2528583 4.7378% | $3.04 | 1 | 0 | +40.95% |